Trials / Unknown
UnknownNCT05277493
A Registry of Chinese AL Amyloidosis Patients Treated With Subcutaneous or Intravenous Daratumumab
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 500 (estimated)
- Sponsor
- Peking Union Medical College Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The purpose of this protocol is to generate a registry of Chinese patients with AL amyloidosis treated with subcutaneous/intravenous daratumumab alone or subcutaneous/intravenous daratumumab combined with chemotherapy.
Conditions
Timeline
- Start date
- 2022-03-30
- Primary completion
- 2025-03-01
- Completion
- 2025-09-01
- First posted
- 2022-03-14
- Last updated
- 2022-04-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05277493. Inclusion in this directory is not an endorsement.